Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2955 SEK | +7.07% | +39.39% | -97.04% |
22/05 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
16/05 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
End-of-day quotes
Compared values
Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
---|---|---|---|---|---|---|---|---|---|---|---|
XBRANE BIOPHARMA AB | Other Biotechnology & Medical Research | +7.07% | +39.39% | -97.04% | -99.62% | -99.21% | 39.78M |
Technical Rankings Surperformance
- Stock Market
- Equities
- XBRANE Stock
- Charts Xbrane Biopharma AB
- Comparison Chart